Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 323 clinical trials
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

abdominal pain
crohn's disease
immunomodulators
endoscopy
corticosteroids
  • 918 views
  • 26 Jul, 2022
  • 385 locations
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

remission
abdominal pain
crohn's disease
  • 987 views
  • 10 Aug, 2022
  • 480 locations
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease

ileitis
abdominal pain
ustekinumab
fistulising crohn's disease
colitis
  • 861 views
  • 16 May, 2022
  • 443 locations
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 (JUNIPER)

moderately to severely active Crohn's disease who were previously enrolled in the etrolizumab Phase III Study GA29144 (NCT02394028) and who meet eligibility criteria for enrollment into Part 1. In Part 2

crohn's disease
  • 372 views
  • 15 Jul, 2022
  • 10 locations
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

severe Crohn's disease or moderate to severe Ulcerative Colitis.

ulcerative colitis
colitis
ulceration
crohn's disease
  • 0 views
  • 27 Jul, 2022
  • 21 locations
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is

certolizumab pegol
vedolizumab
ustekinumab
tumor necrosis factor
tumour necrosis
  • 207 views
  • 26 Jul, 2022
  • 320 locations
Study to Assess Efficacy and Safety of Cx601 Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)

The purpose of this study is to evaluate the combined remission of complex perianal fistulas, defined as the clinical assessment at Week 24 of closure of all treated external openings that were draining at baseline despite gentle finger compression, and absence of collections greater than (>) 2 centimeter (cm) (in …

abdominal pain
certolizumab pegol
monoclonal antibodies
vedolizumab
ustekinumab
  • 236 views
  • 02 Dec, 2021
  • 178 locations
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis

with Crohn's ileitis or Crohn's ileocolitis requiring resection will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.

ileitis
tumor necrosis factor alpha
tumor necrosis factor
tumour necrosis
ileocolitis
  • 14 views
  • 14 Apr, 2022
  • 12 locations
  • 0 views
  • 19 Aug, 2022
  • 42 locations
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease (AIM-CD)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight

certolizumab pegol
ustekinumab
vedolizumab
natalizumab
ileal disease
  • 19 views
  • 29 Jul, 2022
  • 96 locations